proquad market share, proquad market, proquad market size, proquad market demand, proquad market forecast, proquad market growth
How large is the proquad market, and what is its growth trajectory?
The proquad market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to established immunization schedules, combination vaccine advantages, government-supported vaccination programs, epidemic outbreaks, strong healthcare infrastructure, and regulatory approvals.
The proquad market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to population growth, improved access to healthcare, global health initiatives, rising awareness of vaccine-preventable diseases, government vaccination funding, and a growing focus on preventive healthcare. Major trends in the forecast period include global vaccination coverage, technological advancements in vaccine delivery, integration of vaccines in routine health systems, improvements in vaccine accessibility, and increased awareness of vaccine safety.
Get Your Free Sample of The Global Proquad Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp
What are the key forces behind the proquad market’s growth in recent years?
The rising incidence of measles and chickenpox is expected to propel the growth of the proquad market going forward. Measles is a highly contagious viral infection characterized by fever, cough, and a red rash, preventable through vaccination, while chickenpox is a contagious disease caused by the Varicella-zoster virus, marked by an itchy blister-like rash and preventable with a vaccine. Measles and chickenpox cases are rising due to declining vaccination rates, misinformation about vaccines, increased global travel, and outbreaks in unvaccinated populations, leading to the re-emergence of these preventable diseases. Proquad, a combination vaccine for measles, mumps, rubella, and varicella (chickenpox), helps protect against these diseases by providing immunity through a single dose, reducing the risk of infection, controlling outbreaks, and ensuring comprehensive coverage to prevent complications associated with measles and chickenpox. For instance, in May 2024, according to the World Health Organization, a Switzerland-based non-profit organization, 56,634 measles cases and four deaths were officially reported across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Therefore, the rising incidence of measles and chickenpox is driving the growth of the proquad market.
What are the major segments of the proquad market?
The proquad market covered in this report is segmented –
1) By Indication: Measles; Mumps; Rubella; Varicella
2) By Patient Type: Pediatric Patient; Adult Patient
3) By End User: Healthcare Providers; Pharmacies; Public Health Organization
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/proquad-global-market-report
Which companies dominate the proquad market?
Major companies operating in the proquad market are Merck and Co. Inc.
What major trends will shape the proquad market during the forecast period?
A key trend in the proquad market is the focus on expansion of vaccine administration options such as intramuscular (IM) administration to enhance convenience and consistency in immunization practices. Intramuscular (IM) administration refers to the delivery of a vaccine or medication directly into the muscle tissue, allowing for faster absorption into the bloodstream. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for the addition of an intramuscular (IM) administration option to the U.S. Product Insert (USPI) for its MMRV vaccine family, including ProQuad. With this approval, the MMRV family joins other commonly recommended vaccines that can be given intramuscularly. Healthcare professionals in the U.S. now have the option to administer all routinely recommended injectable pediatric vaccines in the CDC immunization schedule via the same IM route. M-M-R II, VARIVAX, and ProQuad are the only measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. The MMRV family of vaccines is also licensed for IM use in the European Union.
What are the key regional dynamics of the proquad market, and which region leads in market share?
North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Proquad Market Report 2025 Offer?
The proquad market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Proquad is a vaccine designed to protect against measles, mumps, rubella (MMR), and varicella (chickenpox). It is a combination vaccine, meaning it combines multiple vaccines into one shot to reduce the number of injections needed for immunization. It is used primarily in children, typically administered as a single dose for those between 12 months and 12 years of age.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
